S. P. M. Filho

BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.

M. Tsao, O. Ludkovski, F. Shepherd, 2020, Lung cancer.